Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKB589 plus CAPOX and sintilimab as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20223056Phase 2Active
- Sponsor
- Aosaikang Biotherapeutics
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ASKB589, sintilimab, oxaliplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Aosaikang Biotherapeutics. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Jan 2023; status: active.
02
Drugs
ASKB589sintilimaboxaliplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20223056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223056.